Study of two-drug combo for advanced bile duct or gallbladder cancer
Part of Cancer, Digestive system clinical trials.
This study tests a new combination of two drugs for advanced bile duct or gallbladder cancer that has not responded to first-line immunotherapy and chemotherapy. The drugs target the TROP2 protein on cancer cells and boost the immune system to fight the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have bile duct or gallbladder cancer that is advanced or has spread, and cannot be removed by surgery.
- Your cancer had immunotherapy (PD-1/PD-L1 checkpoint inhibitor) combined with chemotherapy as first treatment, but it got worse during or after that treatment.
- Your tumor has a high level of a marker called TROP2 (test score 2+ or 3+).
- You have at least one tumor that can be measured on scans, and you are in generally good health (able to do daily activities).
- You have not had cancer spread to the brain, serious eye conditions, or certain heart or bleeding problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, sacituzumab tirumotecan and pembrolizumab, for people with advanced bile duct or gallbladder cancer that has grown after previous treatment. The goal is to see if this combination can shrink tumors or slow the cancer's growth.
This trial tests a new drug combination (Trop-2 antibody-drug conjugate plus other therapies) for advanced triple-negative breast cancer that has spread or come back. It may offer a new option for people who have had only 1–2 prior chemotherapies and have not used immunotherapy or anti-angiogenic drugs before.
This trial tests a combination of three drugs (trastuzumab rezetecan, adebrelimab, and lenvatinib) for people with advanced bile duct or gallbladder cancer that has HER2 protein on its cells. The goal is to see if this combination can help shrink tumors or slow the cancer's growth.
This trial tests a combination of two immunotherapy drugs, chemotherapy, and a targeted therapy to shrink bile duct or gallbladder cancers that are advanced but might be removable with surgery. The goal is to see if this approach can make surgery possible and improve outcomes.
This trial tests a combination of two drugs, sacituzumab tirumotecan and pucotenlimab, for people with advanced bile duct cancer (including gallbladder cancer) that cannot be removed by surgery or has spread. The goal is to see if this treatment is safe and works well, especially for those with a protein called TROP2 on their cancer cells.
This trial tests a new drug called sacituzumab tirumotecan for people with advanced bile duct cancer that has grown after previous treatment. The drug targets a protein called TROP2 on cancer cells and may help shrink tumors or slow the disease.
Hear when a new Advanced Biliary Tract Cancers trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.